This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (41)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Connective Tissue Diseases  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Monika Srivastava, BS; Adrienne Rencic, MD, PhD; Gerardine Diglio, BS; Helen Santana, BS; Paula Bonitz, BS; Rosemarie Watson, MD; Esther Ha, BA; Grant J. Anhalt, MD; Thomas T. Provost, MD; Carlos H. Nousari, MD

Arch Dermatol. 2003;139:45-49.

Objective  To study the clinical and immunopathologic findings of drug-induced, Ro/SSA-positive cutaneous lupus erythematosus (CLE).

Design  Retrospective medical and laboratory record review.

Setting  Immunodermatology Division of Johns Hopkins Hospital (Baltimore, Md).

Patients  Of 120 patients found to have anti-Ro/SSA antibodies by hemagglutination and/or double immunodiffusion, 70 had clinical and immunopathologic confirmation of CLE. Fifteen of these 70 patients had a history of new drug exposure, defined as less than 6 months, associated with disease development.

Results  The disease-associated drugs included hydrochlorothiazide (5 patients), angiotensin-converting enzyme inhibitors (3 patients), calcium channel blockers (3 patients), interferons (2 patients), and statins (2 patients). The most common presentations were photodistributed diffuse erythema and subacute CLE-type lesions without evidence of significant systemic disease. All specimens revealed interface dermatitis and fine granular IgG deposition along the basement membrane zone and throughout the epidermis. Most patients experienced improvement or resolution of clinical lesions within 8 weeks and decrease of Ro/SSA titers within 8 months after discontinuation of drug treatment.

Conclusions  Antihypertensive drugs are the most commonly associated with Ro-positive CLE. Clinical and immunopathologic features of this drug-induced variant do not seem to differ from the idiopathic disease. In most cases, the disease improves or resolves on discontinuation of the offending drug treatment. It is not known if these drugs precipitate disease in patients who have subclinical disease. Drug-induced Ro/SSA-positive CLE should be included on the differential diagnosis in patients presenting with photosensitive or subacute CLE-type eruptions.

From the Division of Immunodermatology, Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, Md. Dr Nousari is now with the Division of Dermatopathology, Department of Dermatology, University of Pennsylvania, Philadelphia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Drug-induced lupus: an update on its dermatologic aspects
Marzano et al.
Lupus 2009;18:935-940.
ABSTRACT  

Association of Cigarette Smoking but Not Alcohol Consumption With Cutaneous Lupus Erythematosus
Boeckler et al.
Arch Dermatol 2009;145:1012-1016.
ABSTRACT | FULL TEXT  

Chemotherapy-induced subacute lupus erythematosus
Guhl et al.
Lupus 2009;18:859-860.
 

Clinically Relevant Information About Cutaneous Lupus Erythematosus
Callen
Arch Dermatol 2009;145:316-319.
FULL TEXT  

DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus
Han et al.
Int Immunol 2008;20:1067-1075.
ABSTRACT | FULL TEXT  

Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial
Ferreira et al.
Rheumatology (Oxford) 2007;46:1560-1565.
ABSTRACT | FULL TEXT  

Drug-induced lupus: an update
Vasoo
Lupus 2006;15:757-761.
ABSTRACT  

UV-B Phototoxic Effects Induced by Atorvastatin.
Marguery et al.
Arch Dermatol 2006;142:1082-1084.
FULL TEXT  

Inhalation Route Inducing Subacute Cutaneous Lupus Erythematosus With Tiotropium
Pham and Saurat
Arch Dermatol 2005;141:911-912.
FULL TEXT  

Statins: immunomodulators for autoimmune rheumatic disease?
Jury and Ehrenstein
Lupus 2005;14:192-196.
ABSTRACT  

Ro/SSA-Positive Cutaneous Lupus Erythematosus Induced by Carbamazepine
Capponi et al.
Arch Dermatol 2005;141:103-104.
FULL TEXT  

Statins and lupus erythematosus
Noel
Rheumatology (Oxford) 2004;43:397-398.
FULL TEXT  

Risks and Benefits of Statins in Lupus Erythematosus
Noel
Arch Intern Med 2004;164:107-108.
FULL TEXT  

Frequency of Drug-Induced Cutaneous Lupus Erythematosus
Journal Watch Dermatology 2003;2003:5-5.
FULL TEXT  

How Frequently Are Drugs Associated With the Development or Exacerbation of Subacute Cutaneous Lupus?
Callen
Arch Dermatol 2003;139:89-90.
FULL TEXT